Drugs / anti-CD20/CD30-CAR T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06756321 | Sep 2023 → Mar 2025 overdue | leukemia, lymphoma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD20/CD30-CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756321 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” NCT06756321 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT06756321 ↗ |